Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT03363217 is registered in ClinicalTrials.gov with St. Justine's Hospital as lead sponsor.

NCT NCT03363217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Lead sponsor
St. Justine's Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 16, 2018
Completion date
March 1, 2027
Enrollment
114 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system glioma, low-grade glioma, plexiform neurofibroma